Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
J2H-2301
- Development stage
- Preclinical
- Lead developer
- J2H Biotech
- Modality
- Small Molecules
01
Overview
J2H-2301 is an early-stage small molecule therapeutic candidate being developed by J2H Biotech. It is designed to target an undisclosed novel biological pathway for the treatment of solid tumors. The program is currently in the discovery phase of development.
Beyond the preview
Go deeper on J2H-2301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on J2H-2301.